BRCA Single Gene denied due to quantity / dose limits by Aetna?

Aetna's specific coverage criteria for brca single gene are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Applied a Quantity Limit to Your BRCA Single-Gene Test

Quantity-limit denials on genetic tests like BRCA single-gene testing typically arise when Aetna's system flags that a similar test has already been performed and covered within a defined lookback period, or when the number of gene panels or tests ordered exceeds a policy-defined ceiling. The underlying rationale is that germline BRCA variants do not change over time, so retesting the same individual is ordinarily unnecessary. However, there are legitimate clinical scenarios — such as a prior inconclusive result, a change in testing technology that offers improved accuracy, or a new affected family member warranting cascade testing — where repeat or additional testing is medically warranted.

## Your Federal Appeal Rights

• Internal appeal: File within the window shown on your Explanation of Benefits. Aetna must respond within 30 days (pre-service) or 60 days (post-service) of receiving a complete appeal.
• External review (ACA §2719 / ERISA §503): After a final internal denial, you generally have four months to request independent external review. An accredited independent review organization — not Aetna — evaluates the clinical basis of the limit.
• Expedited review: If delay poses an imminent clinical risk (e.g., treatment decision is pending), request expedited review for a decision typically within 72 hours.

## What to Gather

1. Prior test records — results and reports from any previous BRCA test, including the lab, date, methodology, and outcome (conclusive/inconclusive/variant-of-uncertain-significance). 2. Clinical rationale for additional testing — your clinician's letter should explain specifically why the quantity limit does not apply: e.g., the prior test was performed with an older platform, returned a VUS, or tested a different gene than the one now in question. 3. Aetna's published Clinical Policy Bulletin — obtain the current version and identify the exact quantity-limit provision being applied. 4. Applicable guideline reference — the relevant NCCN or ACMG guideline should be cited to establish that repeat or cascade testing meets the standard of care in this clinical context. 5. Family cascade-testing context — if this is a family member being tested after a known pathogenic variant was identified in a relative, document the proband's confirmed result and the clinical relationship.

## Criteria-Mapping Structure

Identify the specific quantity-limit clause in Aetna's policy. List every exception or override condition the policy recognizes and map each one to the facts of the case. If no explicit exception applies, your clinician's letter should make the case that the clinical circumstances fall outside the scope of what the quantity limit was designed to address, citing guideline support.

## Bottom Line

Quantity-limit denials for BRCA single-gene testing are most successfully challenged when there is a clear, documented clinical reason why a prior test does not satisfy the current clinical need. Precision in the appeal — addressing the policy's exact language — makes the difference.